The AKAP9 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population originating from the A-549 human lung epithelial carcinoma cell line. This product delivers a heterogeneous mix of AKAP9-disrupted alleles, creating a versatile loss-of-function model for studying the roles of A-kinase anchoring protein 9 (AKAP9) in cellular signaling and architecture. As a polyclonal knockout pool, it avoids clonal selection bias and captures a range of functional perturbations, making it ideal for bulk biochemical, imaging, and functional genomics experiments. The cells retain the parental A-549 background and are amenable to standard culture and transfection protocols.
The parental A-549 cell line is derived from a 58-year-old male with lung adenocarcinoma and exhibits adherent epithelial morphology. These adenocarcinomic alveolar basal epithelial cells serve as a well-established model of non-small cell lung cancer (NSCLC), widely used to study oncogenic signaling, drug resistance, and metastatic potential. A-549 cells express characteristic epithelial markers and maintain robust proliferation, offering a physiologically relevant context for investigating AKAP9-dependent mechanisms in lung cancer progression where centrosome abnormalities are common.
AKAP9 is a master scaffold that anchors PKA holoenzymes via regulatory subunits (RI/RII) to centrosomes and the Golgi, achieving spatial control of cAMP-driven phosphorylation. At the centrosome, AKAP9 facilitates PKA-mediated phosphorylation of substrates such as Nek2 and CDK2, essential for centriole disjunction and cell cycle progression. It also interacts with calcineurin, PP2A, and PDE4D3 to fine-tune local signaling dynamics. Upstream, GPCR-activated adenylyl cyclase generates cAMP, while Aurora A kinase phosphorylates AKAP9 to modulate its scaffolding functions. Downstream, AKAP9 recruits microtubule-associated proteins like CLIP-170 and p150Glued, and its Golgi pool binds GM130 to direct mitotic Golgi reassembly. Knockout of AKAP9 disrupts these processes, causing centrosome duplication defects, microtubule disorganization, and Golgi fragmentation.
In the A-549 lung adenocarcinoma context, loss of AKAP9 is expected to compound centrosomal defects and genomic instability, as dysregulated PKA signaling at the centrosome impairs mitotic progression. Resulting aneuploidy and disrupted microtubule organization are hallmarks of aggressive NSCLC. Furthermore, defective Golgi reassembly from AKAP9 deficiency may alter secretory trafficking and cell migration, contributing to metastatic behavior. This model therefore links cAMP/PKA pathway disruption to key cancer phenotypes and supports mechanistic and therapeutic investigations.
Researchers can utilize these polyclonal knockout cells for a range of assays including western blot detection of AKAP9 and phospho-PKA substrates, immunofluorescence analysis of centrosome markers (??-tubulin, pericentrin), and flow cytometric cell cycle profiling. Mitotic index determination and Golgi morphology analysis via GM130 staining offer additional functional readouts. Functional studies such as migration, invasion, viability, and drug sensitivity screening can elucidate AKAP9??s role in lung cancer progression and therapy response. The model also serves as a platform for investigating cardiac arrhythmia mechanisms by heterologous expression of ion channels, facilitating long QT syndrome type 11 research. For additional product information or to discuss custom solutions, please contact Ascent Research.
